Press releases

All press releases Regulatory

Regulatory press release 2023-05-25

Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)

Regulatory press release 2023-05-16

Bulletin from the 2023 annual general meeting of Xspray Pharma AB (publ)

Regulatory press release 2023-05-04

Interim Report First Quarter 2023

Regulatory press release 2023-05-02

Notice of extraordinary general meeting in Xspray Pharma AB (publ)

Regulatory press release 2023-05-02

Xspray announces a rights issue of units of approximately SEK 300 million ahead of Dasynoc product launch

Press release 2023-04-26

Xspray Pharma receives expected partial decision in patent case regarding matter of law

Regulatory press release 2023-04-13

Notice of annual general meeting of Xspray Pharma AB (publ)

Regulatory press release 2023-03-29

Xspray Pharma publishes its Annual Report 2022

Press release 2023-03-13

Board member in Xspray Pharma acquires shares from the CEO

Regulatory press release 2023-02-23

Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)

IR contact

Kerstin Hasselgren, IRO / Senior Adviser

+46 (0)70 311 16 83

info@xspray.com

Subscribe